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EDTA/glycine-acid (EGA) has been reported to remove IgG-bound
antibodies from red blood cells (RBCs) and to denature Kell system
and Era antigens.  EGA-treated RBCs were tested in parallel with
chloroquine diphosphate (CDP)-treated RBCs to evaluate whether
EGA would remove Bg antigens from RBCs as efficiently as CDP.
Fifty-seven serum/plasma samples containing known Bg antibodies
were tested with untreated Bg+ RBCs, EGA-treated Bg+ RBCs, and
CDP-treated Bg+ RBCs by an indirect antiglobulin test (IAT), using a
low-ionic-strength additive solution and murine monoclonal polyspe-
cific antiglobulin reagent.  Of 57 samples, 40 (22 anti-Bga, 17 anti-Bgb,
and 1 Bg-related) were nonreactive by IAT with EGA-treated RBCs
and CDP-treated RBCs, 14 (7 anti-Bga, 4 anti-Bgb, and 3 Bg-related)
were nonreactive by IAT only with EGA-treated RBCs, none were
nonreactive in IAT with only CDP-treated RBCs, and 3 (anti-Bga) were
still reactive by IAT with EGA-treated RBCs and CDP-treated RBCs.
Therefore, EGA strips Bg antigens from RBCs.  Our results indicate
EGA treatment is more efficient and requires less time (1–2 minutes)
to perform than the CDP procedure (30–120 minutes) for removal of
Bg antigens from RBCs.  Immunohematology 1999;15:66–68.
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EDTA/glycine-acid (EGA) treatment has been report-
ed to remove IgG-bound antibodies from red blood cells
(RBCs).1,2 All common RBC antigens were reported to
be detected on EGA-treated RBCs, with the exception of
Kell system antigens.1,3 Liew and Uchikawa4 reported
the loss of the high-incidence antigen Era when using
EGA treatment. It also has been reported that EGA strips
HLA antigens from platelets.5
Chloroquine diphosphate (CDP) treatment also has
been reported to remove IgG-bound antibodies from
RBCs.6 The RBC membrane remains intact with no
apparent loss of antigen reactivity. If incubation is car-
ried out at 37°C for 30 minutes rather than at room tem-
perature (RT), slight hemolysis and/or tanning of the
RBCs and a decrease in antigen strength of M, Jka, Jkb,
Doa, and Dob blood group antigens may occur.7-9 It has
been reported that the CDP treatment strips Bg antigens
from RBCs.8,10 This procedure is useful in antibody iden-
tification when a patient’s serum reacts unexpectedly
with Bg+ commercial reagents or donor RBCs.
Because both the EGA and CDP techniques remove
IgG-bound antibodies from RBCs,and CDP also strips Bg
antigens from RBCs,our laboratory conducted a study to
evaluate whether EGA would also remove Bg antigens
from RBCs and be as efficient as CDP.
Materials and Methods
In our study, 57 serum/plasma samples containing
known anti-Bga, -Bgb, or Bg-related antibodies were test-
ed with untreated Bg+ RBCs,EGA-treated Bg+ RBCs, and
CDP-treated Bg+ RBCs in parallel by the indirect
antiglobulin test (IAT). Each aliquot of Bg+ RBCs was
treated with EGA according to the procedure previously
described by Louie et al.1 One volume of 10% EDTA was
added to four volumes of glycine-HCl buffer (pH 1.5). To
this mixture, one volume of washed, packed RBCs was
added and incubated at RT for 1 to 2 minutes. One vol-
ume of 1.0 M TRIS-NaCl was added to adjust the mixture
to a neutral pH. This procedure was performed without
interruption to prevent EDTA precipitation or RBC
hemolysis. After centrifuging, the supernate was
removed and the RBCs were washed × 3 with physio-
logic saline. The washed RBCs were resuspended to a 3
to 4% suspension in physiologic saline or modified
Alsever’s solution (Gamma Biologicals, Houston,TX) for
testing.
Another aliquot of each Bg+ RBC sample was also
treated with CDP according to the manufacturer’s direc-
tions. Four volumes of chloroquine diphosphate
(Gamma-Quin™,Gamma Biologicals) were added to one
volume of washed, packed RBCs. The tube was mixed
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and incubated at RT for up to 2 hours. The mixture was
washed × 4 with physiologic saline and resuspended to
a 3 to 4% suspension in physiologic saline or modified
Alsever’s solution for testing.
The untreated Bg+ RBCs, the EGA-treated Bg+ RBCs,
and the CDP-treated Bg+ RBCs were tested in parallel by
the IAT. A standard low-ionic-strength (LISS) solution
additive tube technique was employed.11 Two drops of
serum/plasma, one drop of a 3 to 4% RBC suspension
(untreated, EGA-treated, or CDP-treated) and two drops
of the LISS additive (Gamma Biologicals) were mixed
together and incubated at 37°C for 30 minutes. All tests
were washed × 4 with physiologic saline and murine
monoclonal polyspecific anti-human globulin reagent
(Gamma Biologicals) was added. All tests were inspect-
ed for macroscopic and microscopic agglutination.
Reactivity was graded and recorded according to the
methods described in the Technical Manual of the
American Association of Blood Banks.11 Microscopic
reactions were graded like macroscopic reactions, i.e.,
based on the number of agglutinates present. All nega-
tive tests were confirmed by the addition of IgG-coated
RBCs.
Results
Of the 57 samples containing Bg antibodies, 40 (22
anti-Bga, 17 anti-Bgb, and 1 Bg-related) were nonreactive
by IAT with EGA-treated RBCs and CDP-treated RBCs,14
(7 anti-Bga,4 anti-Bgb,and 3 Bg-related) were nonreactive
by IAT only with EGA-treated RBCs, none were nonreac-
tive by IAT only with CDP-treated RBCs, and 3 (anti-Bga)
were still reactive by IAT with EGA-treated RBCs and
CDP-treated RBCs (Table 1). The strength of reactivity of
the Bg antibodies with the untreated Bg+ RBCs ranged
from microscopic to 2+ macroscopic by IAT.
Table 1. Results of EGA and CDP treatments of Bg+ red blood cells (RBCs)
Bg-related
Results anti-Bga anti-Bgb antibodies Total
Nonreactive with EGA- 22 17 1 40
and CDP-treated RBCs
Nonreactive with EGA- 7 4 3 14
treated RBCs, reactive 
with CDP-treated RBCs
Reactive with EGA-treated 0 0 0 0
RBCs, nonreactive with 
CDP-treated RBCs
Reactive with EGA- and 3 0 0 3
CDP-treated RBCs
Table 2 shows the 14 Bg antibodies that were nonre-
active with EGA-treated RBCs but still reactive with CDP-
treated RBCs. Seven of the antibodies exhibited the
same strength of reactivity by IAT with CDP-treated
RBCs as with untreated RBCs. The reactivity of the other
seven antibodies was decreased by IAT with CDP-treat-
ed RBCs as compared with the reactivity with untreated
RBCs. CDP did not completely remove the Bg antigens
from the RBCs, whereas EGA appeared to completely
strip the Bg antigens from the RBC membranes. Three
examples of anti-Bga were still reactive by IAT with EGA-
treated RBCs and CDP-treated RBCs.
Table 2. Bg antibodies reactive with CDP-treated RBCs by indirect 
antiglobulin test
Untreated CDP-treated EGA-treated
Antibody Case RBCs RBCs RBCs
anti-Bga B2368 1+ 1+ 0‡
B0780f 1+w 1+w 0
Marsden 2+ 2+ 0
B0829 1+s 0/3 0
B2465 0/2* 0/1 0
B2347 0/3 0/1 0
Court r†/4 0/1 0
anti-Bgb B2498 +w +w 0
62X04460 1+ 1+ 0
B2510 r/4 0/2 0
B2507 1+s r/4 0
Bg-related B2418 2+ 2+ 0
B2475 + + 0
B2449 1+ + 0
* 0/1 to r/4 (macroscopic and microscopic readings)
† rough
‡ macroscopic and microscopic readings nonreactive
Discussion
The EGA and CDP treatments strip Bg antigens from
RBCs. Both the EGA and the CDP treatments have
advantages and limitations. The advantages of EGA treat-
ment are that it can be performed in less than 2 minutes
and appears to be more efficient in the removal of Bg
antigens than CDP. All three solutions for this treatment
are commercially available as a kit and can be stored at
RT. A limitation of the EGA treatment is that Kell system
and Era antigens are also destroyed.
The advantages of CDP treatment are that it requires
less manipulation and does not destroy Kell system and
Era antigens. CDP also is commercially available, but it
must be stored at 2° to 8°C. The limitations of this pro-
cedure are that CDP treatment may take up to 2 hours to
strip Bg antigens from RBCs, and our data suggest it is
not as efficient as EGA for removal of these antigens.
The three examples of anti-Bga that were still reactive
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by IAT with EGA-treated RBCs and CDP-treated RBCs
were only reactive with commercial reagent RBCs
and/or donor RBCs that typed Bg(a+). It is possible that
the Bg(a+) RBCs also were positive for another HLA-
related RBC antigen, which was not stripped from the
RBCs by either EGA or CDP treatments. If additional
RBC samples from these Bg(a+) donors become avail-
able, complete HLA typing will be performed.
Acknowledgments
We thank Ms. R. Quiroz for secretarial assistance.
References
1. Louie JE, Jiang AF, Zaroulis CG. Preparation of intact
antibody-free red blood cells in autoimmune
hemolytic anemia (abstract). Transfusion 1986;
26:550.
2. Byrne PC. Use of a modified acid/EDTA elution tech-
nique. Immunohematology 1991;7:46–7.
3. Julleis J, Sapp C, Kakaiya R. Glycine-EDTA as a sub-
stitute for AET in the inactivation of Kell System anti-
gens on red blood cells (abstract). Transfusion
1992;32:14S.
4. Liew YW, Uchikawa M. Loss of Era antigen in very
low pH buffers (letter). Transfusion 1987;27:442–3.
5. Sinor LT, Stone DL, Young R, et al. Comparison of
chloroquine and acid elution methods for removal of
platelet HLA antigens (abstract). Transfusion 1992;
32:14S.
6. Edwards JM, Moulds JJ, Judd WJ. Chloroquine disso-
ciation of antigen-antibody complexes. Transfusion
1982;22:59–61.
7. McShane K, Cornwall W. Chloroquine reduces anti-
gen strength (letter). Transfusion 1985;25:83.
8. Chen J, Spruell P, Moulds M. Studies using chloro-
quine diphosphate to strip HLA A and B antigens
from red blood cells (RBCs) (abstract). New
Orleans: ISBT/AABB Joint Congress 1990:152.
9. Beaumont AE, Stamps R, Booker DJ, Sokol RJ. An
improved method for removal of red cell-bound
immunoglobulin using chloroquine solution.
Immunohematology 1994;10:22–4.
10. Swanson JL, Sastamoinen R. Chloroquine stripping
of HLA A,B from red cells (letter). Transfusion
1985;25:439–40.
11. Vengelen-Tyler V, ed. Technical manual. 12th ed.
Bethesda, MD:American Association of Blood Banks,
1996.
Kayla D. Champagne, MT(ASCP), Consultation and
Education, Gamma Biologicals, Subsidiary of
Immucor, 3700 Mangum Road, Houston, TX  77092;
Peggy Spruell, MT(ASCP)SBB; Jane Chen, MD
(Shanghai); Leslie Voll, MS, MT(ASCP)SBB; and Gloria
Schlanser, MT(ASCP), Gamma Biologicals, Subsidiary
of Immucor, Houston, TX.
I M M U N O H E M A T O L O G Y ,  V O L U M E  1 5 ,  N U M B E R  2 ,  1 9 9 968
Attention: Presidents of State Blood Bank Associations—In order to increase the number of subscribers
to Immunohematology, we are soliciting membership lists of your organizations. Upon receipt of such a list,
each person will receive a complimentary copy of Immunohematology, and, if desired, a personal letter from
the association president. For further information, contact: Mary H. McGinniss, Managing Editor, by phone or
fax at (301) 299-7443.
